COVID-19 Research at IITs

Project Title : Towards large scale Production of Recombinant Proteins for Vaccine and Testing of Novel COVID-19 to produce reagents for the development of indigenous vaccine.

Expected Outcome : Recombinant proteins may be used for 1. Vaccine candidate. 2. Production of antiviral therapeutics. 3. Production of monoclonal antibody for testing. 4. Production of humanized antibodies for therapy.
Expected Timeline : 1.5 years
Remarks : Funding required Rs. 60.0 Lakh
URL :
Additional Info
PI Details : Sudip K. Ghosh, Ananta K. Ghosh and Ramkrishna Sen, [email protected]; [email protected]; [email protected]

Project Title : Telemedicine for fighting viral pandemic such as COVID-19

Expected Outcome : The software will be developed as specialized modules of an existing telemedicine system iMediX. This will make the prototyping fast. Specialized apps will also be developed for interacting with the system from mobile phones. Already a student has been engaged for prototyping home care modules of the system.
Expected Timeline : 2 years
Remarks : Funding required for Rs. 60.0 Lakh
URL :
Additional Info
PI Details : Prof. Jayanta Mukhopadhyay, [email protected]

Project Title : In-situ Gel for Rapid Capture and Inactivation of 2019-nCoV

Expected Outcome : Anti Covid nasal gels / sprays for nasal passages and use on masks
Expected Timeline : One year
Remarks : Project funded by SERB and initiated
URL :
PI Details : Prof. Kiran Kondabagil, Prof. Rinti Banerjee, Prof. Ashutosh Kumar, Prof. Shamik Sen , 022-25767758, 022-25767868, 022-25767762, 022-25767743 , [email protected], [email protected], [email protected], [email protected]

Project Title : World Wide Help: A Proposal

Expected Outcome : IT solution for user-friendly, cost effective and customized information access on any topic and in any domain with humans-in-the-loop.
Expected Timeline : Solution available, can be customized as per requirement
Remarks :
URL : https://www.facebook.com/permalink.php?id=301908303167310&story_fbid=3129807277044051
PI Details : Prof. Kameswari Chebrolu , 022-25767976 , [email protected]

Project Title : Plasma Proteomic Analysis of COVID-19 patients to identify the potential biomarkers and therapeutic targets: A Pilot Study

Expected Outcome : Identification of potential therapeutic targets and better understanding of the disease pathobiology.
Expected Timeline : Three months
Remarks : Project initiated
URL :
PI Details : Prof. Sanjeeva Srivastava, Department of Biosciences and Bioengineering in collaboration with Dr. Om Shrivastav, Director, Infectious Diseases, Jaslok Hospital, Mumbai; Dr. Jayanthi S. Shastri, Professor & Head (Microbiology) T N Medical College & Nair Hospital and Dr. Mala Vinod Kaneria, Infectious , 022-25767779 , [email protected]

Project Title : Identification of global metabolite biomarkers in COVID-19 infected patients for targeted therapy

Expected Outcome : identification of potential therapeutic targets and better understanding of the disease pathobiology.
Expected Timeline : one year
Remarks : Project funded by DST, GoI
URL :
PI Details : Prof. Sanjeeva Srivastava, Department of Biosciences and Bioengineering in collaboration with Dr. Om Shrivastav, Director, Infectious Diseases, Jaslok Hospital, Mumbai; Dr. Jayanthi S. Shastri, Professor & Head (Microbiology) T N Medical College & Nair Hospital and Dr. Mala Vinod Kaneria, Infectious , 022-25767779 , [email protected]

Project Title : A Novel First AId Technique for Treating COVID-19

Expected Outcome : A technique that may reduce the requirement of Ventilators.
Expected Timeline : End of May: Scientific and Clinical Validation is remaining
Remarks : This technique is similar to Cardiopulmonary Resuscitation (CPR). The technique is based on Varma system which is a traditional knowledge of India.
URL :
PI Details : Prof. M.Manivannan, Touchlab, IIT Madras , 044-22574064 , [email protected]

Project Title : Ubiqare enables doctor-driven speciality care to patients at home, reducing hospital visits and stays. The Ubiqare solution seamlessly combines clinical telepresence technology, collaboration framework, and last mile clinical network of doctors, nurses, therapists and phlebotomists. Ubiqare has cared for 110+ patients at home, delivered 6200 patient-days of supportive medical care, for serious illnesses like cancer, stroke, MS, cerebral palsy, orthopaedic and few others. 96% of the clinical episodes were managed at home, avoiding as many readmissions. The patients have expressed high levels of satisfaction and improved quality of life.

Expected Outcome : The current objective is to adapt Ubiqare’s Specialty Care Platform to take care of COVID-19 patients during home quarantine and isolation ward stages. The top level features are: • Extension of care of Pulmonologist/ Physician and interactive clinical telepresence • Regular Monitoring by Care Doctors based on vitals entries integrated with EHR • Tele- Triaging and Tele-Consultation by Ubiqare Doctor/ Pulmonologist/ Physician • Enable Collaboration with healthcare workers, path labs and clinical network Outcome Of the total population of COVID patients, over 70% of them would be in Asymptomatic and Mild stages. These patients who are under home quarantine can be treated at home, by ensuring availability of proper clinical care and monitoring. Our solution will support monitoring of these patients, check compliance of the care protocol as well as enable regular tele-consults with doctor. In addition, our solution enables monitoring of patients in the Moderate stage with close supervision of the care flows and clinical interventions. This enables the specialty hospital infrastructure to be leveraged for only those in the stage of Severe Symptoms. In addition, Specialist and Doctors can minimize the physical proximity using the tele-health and remote monitoring features thereby reducing risk of getting infected, while ensuring patient is being monitored and supervised.
Expected Timeline : 6 months
Remarks :
URL :
PI Details : Sundararajan Srinivasan , 9845292075 , [email protected]

Project Title : Creating candidate vaccine against the COVID-19

Expected Outcome : The objective is to create a live attenuated and replication-competent virus vaccines against Novel coronavirus (SARS-CoV-2) to be effective against COVID-19 infection. Simultaneously, we are also aiming for the candidate antivirals, which has potential to stop the viral infection. For this purpose we have designed a cell based in-vitro infectivity assay for screening potential antiviral therapeutics.
Expected Timeline :
Remarks :
URL :
PI Details : Dr. Dibyendu Das , 0512 259 4064 , [email protected]

Project Title : Computational prediction of possible nCoV-19 structural proteins inhibitors from Azadirachta indica (Neem) Five potential compounds screened for CL-3 protease protein of nCov19

Expected Outcome : Inhibitory against replicating virus
Expected Timeline : Project initiated
Remarks :
URL :
PI Details : Prof. Manidipa Banerjee, School of Biological Sciences, IIT Delhi , 011- 2659 7538 , [email protected]

Project Title : Designing virus-like particles as vaccine candidates against nCoV-19 Proposed express M (Membrane), N (Nucleocapsid), E (Envelope) and S (Spike) proteins of nCoV-19 simultaneously in HEK293 cells for generating virus-like particle

Expected Outcome : Generating virus-like particles for immunization against nCoV-19
Expected Timeline : Project initiated
Remarks :
URL :
PI Details : Prof. Manidipa Banerjee, School of Biological Sciences, IIT Delhi , 011- 2659 7538 , [email protected]

Project Title : Targeting n3CLPro main protease, spike surface protein of COVID-19 In silico screening of FDA approved compounds

Expected Outcome : To inhibit main protease activity of virus, which will hinder the virus replications
Expected Timeline : Project initiated
Remarks :
URL :
PI Details : Prof Ashok Patel, School of Biological Sciences, IIT Delhi , 011-2659 7528 , [email protected]

Project Title : Preparation of Disease management Manual for Primary Health Centers (PHCs) and Hospitals

Expected Outcome : All PHCs and Hospitals may follow this guidelines while managing COVID 19 patients
Expected Timeline : Ready
Remarks : This will contain ‘General Advisory’, ‘Quarantine’, ‘Isolation’ and ‘Treatment of positive patients’
URL :
PI Details : Dr. Satadal Saha/ Prof. Dipankar Bandyopadhyay , 9957577337 , [email protected]; [email protected]

Project Title : Re-purposing of FDA drugs and exploitation of ancient Ayurvedic knowledge to discover novel inhibitors to block coronavirus propagation.

Expected Outcome : Coronavirus (CoVID-19) is a new outbreak of coronavirus disease which started in the Wuham, China, the spread of this virus has now reached a global stage, urgent need is therefore needed to find new drug molecules which can either be used as a first aid intervention or slow down the multiplication rate of the virus within the system. In order to address this, the proposed research looked into the existing FDA drugs, bioactive peptides, Ayurvedic formulations and screened them for their inhibitory properties towards the CoVID-19 protease. Recently, the crystal structure of the CoVID-19 protease (6LU7) has been established, this gave us the possible drug target site in CoVID -19. Using, MOE software, we will screen molecules from different libraries and ultimately test the binding affinity of top hits with protein using ITC. The current findings might be suitable for Fragment Based Drug Design (FBDD) approach which might lead to the discovery of completely new drug entity. Stability of the new protein structure will be studied using GROMACS molecular dynamic simulation software. Finally, current project proposal might be useful in identifying treatment for controlling coronavirus infection to cure patients.
Expected Timeline :
Remarks :
URL :
PI Details : Vishal Trived, [email protected]

Project Title : The research aims to optimize ultraviolet (254 nm initially) irradiation of an infected patient's blood to improve the immunity of the host while not adversely affecting the host and investigating the effect on the RNA of the virus. Another plan is to investigate recuperative effect due to irradiation of lung tissue by UV. Before the advent of antibiotics, published research indicates that such ultraviolet blood irradiation at low doses has a considerable positive effect on the immune system.

Expected Outcome : Either a catheter or external continuous flow based UV blood irradiation device to improve the immunity of infected patients to the virus.
Expected Timeline : 2 years from date of funding
Remarks :
URL :
PI Details : Dr. Walia (AIIMS Rishikesh) and Dr. Vellanki (IITR)-equal contribution , 8800492549 and 9557228965 , [email protected] and Bhanu Vellanki <[email protected]></[email protected]>

Project Title : Title: Machine learning based approach to optimize novel small molecules followed by synthesis, in-vtro and in-vivo validation towards development of novel therapeutics against COVID19 The recent emergence of coronaviruses has considered as the biggest pandemic of this century as it posed a severe threat to the existence of human population. The novel coronavirus (SARS-CoV-2 or COVID19), has led to a worldwide pandemic (Zhou et al., 2020) with approximately 8,00,000 cases and 40,000 deaths reported so far (WHO, 31st March, 2020). In the past, there have been occurrences of epidemics involving the severe acute respiratory syndrome virus (SARS-CoV) in 2003 (Hilgenfeld and Peiris, 2013) and the Middle-East respiratory syndrome virus (MERS-CoV) in 2012 (Zaki et al., 2012). However, the absence of any promising vaccines and therapeutic drugs for these coronaviruses has decelerated the countless efforts to prevent the spread of the SARS-CoV-2 worldwide. In the current project, we have taking an initiative to develop an interdisciplinary team to design, develop and synthesize potential small molecules as COVID19 inhibitor with the help of in-silico structural study followed by AI based drug optimization model. The synthesized small molecules would be further tested using in-vitro system using cloned, over expressed protein and validated with in-vivo mimicking system (both cell culture and mouse model) before testing with real virus samples. Objectives of the current project involves, a) In-silico analysis of sequence, structures, complex and dynamics data of potential targets and their inhibitors which would be further utilized to develop features for development of an in house ML based drug optimization system. b) Synthesis of the optimally designed small molecules c) In-vitro screening of the synthesized molecules using laboratory purified target protein d) In-vivo validation (cell culture and mouse model system) and further testing on real viruses

Expected Outcome : Current project is a multi-target, multi-stage project. Our targets are, a) Therapeutics development against CLPro (An important cysteine protease to process viral polyprotein) b) Therapeutics development against RNA dependent RNA polymerase (RDRP) c) Understanding role of ACE2 receptor in COVID19 infection, and high risk potential for patients with hypertensive symptoms.
Expected Timeline : In silico analysis 1-2 months Mission learning based drug optimization /interaction analysis 2-3 months Rest are experiential procedure depends on the lockdown situation and other factors.
Remarks : The in-silico analysis part would be done by us but we need funding for further proceedings like synthesis of drug, cloning, over expression, purification of enzymes, in-vivo works etc.
URL :
PI Details : Saugata Hazra , +91-8171064462 , [email protected]

Project Title : One of the biggest challenge of COVID 19 research is non-availability of any drugs or vaccines. There are several drug and vaccine development are in pipe-line. But all these might take some time. Also the there is no clue about the future cost of such drugs or vaccines. Therefore, there is a pressing need for search of alternative medicines which probably would be from natural sources and traditionally known for their health beneficial effects. This would help in coming up some rapid therapeutic options since, if found suitable, they may straight reach the patients without much logistics of clinical trial due to their long history of usage or being consumed regularly. But for all these there is need of scientific validation of these alternative medicines which may be formulations or some raw natural products. Now the biggest challenge of developing drugs against COVID 19 is testing procedures which might need handling of live virus and that in turn would need atleast BSL3 facility. This would restrict the aggressive research on drug discovery program only to some sophisticated facilities in India. So in this project we are trying to first establish a mammalian cell based assay system to screen the natural products for their impacts on restricting virus entry to infected person (by mimicking cell based models). Secondly using this developed assay, we would try to screen some phytochemicals and/ or other natural products for their effect on restricting virus infections. Once the proof-of-concept is developed the selected materials will be would be tested in real live pathogenic virus induced animal models at BSL3 or 4 facilities (which be outsourced).

Expected Outcome : (1) Development of some mammalian cell based models to screen potent leads that might inhibit viral infection; (2) Scientific validation of some natural products for their efficacy in the prevention/ cure / management of COVID 19.
Expected Timeline : The project is supposed to be of 24- 36 months’ duration. The main reason being the development of assay and its validation would take some time. Followed by screening an array of natural products for their efficacy to control viral infection
Remarks : The project is an ambitious one since till date there are not much report on the scientific validation of natural products for preventing/ curing/ management of COVID 19 infection. The existing reports are based on some prior reports. There is a need of systematic approach for this. However, the proposal has several challenges, like getting the target genes cloned since only limited information is available regarding their sequences and expression patterns in vitro.
URL :
PI Details : Dr. Partha Roy , 01332 285686/ 9760421411 , [email protected]

Project Title : SARS-CoV-2 a highly contagious and pathogenic virus and is the cause of the ongoing pandemic of coronavirus disease 2019 (COVID-19). Currently, no efficient vaccine or antiviral drugs are commercially available to combat SARS-CoV-2 virus. The current situation is demanding an immediate and quick availability of potential antiviral drug or vaccine which could help to tackle this problem. This increasing demand can be fulfilled by repurposing drugs or molecules targeting key viral replication proteins and host factors that will fasten the process of drug development and will also later tackle the problem of drug resistance SARS-CoV-2. This project aims to identify drug molecules by structure-based repurposing as well as identifying novel antiviral molecules by in silico screening of compound libraries that will be validated for their antiviral potential and binding affinities by biophysical, biochemical, in vitro and in vivo antiviral testing against the virus key enzymes or proteins which are 3CL protease (Mpro), Papain like protease, RNA-dependent RNA polymerase (RdRp), the virus genome capping MTase protein, spike protein. Along with these key viral proteins, we are also targeting the host receptor for SARS-CoV, Angiotensin Converting Enzyme 2 (ACE-2). Our laboratory at IIT Roorkee have successfully screened FDA approved-drug molecules against three proteins, the Mpro protease of SARS-CoV-2, the Spike protein present on envelope of virus and ACE2 receptor responsible for entry and infection of virus into host cell. Currently we are working to screen drugs from more libraries, along with in vitro and in vivo validation of their antiviral potential with the help of our collaborators. Capillary electrophoresis and FRET based assays will be developed for identification as well as biophysical and biochemical characterization of drugs for quick screening and testing of molecules against antiviral drug targets. Selected molecules will be experimentally tested and validated for in vitro and in vivo antiviral efficacy against SARS-CoV2 in collaboration with national research BSL3 facilities and successful candidates can be tested on human COVID19 patients after all ethical and regulatory approvals.

Expected Outcome : The proposed project represents a major step towards identification and development of potential antiviral drug molecules against SARS-CoV-2, to control and combat global pandemic of COVID-19. Potential lead compounds will be identified based on combination of computational methods including in silico virtual screening, molecular docking and simulation studies. These molecules will be experimentally tested biophysically and biochemically. If the molecules show successful antiviral activity in vitro, in vivo and in human trials, these molecules will be used for the treatment of SARS-CoV2 infection.
Expected Timeline : 36 Months
Remarks : Expected timeline: 36 months. 1) Staff recruitment and development of high throughput (HTP) biochemical assays using recombinant viral proteins: 1-6 months 2) Structure-based identification and characterization of antiviral molecules: 7-12 months 3) Biophysical screening using SPR/ITC to identify high affinity binding ligands: 13-18 months 4) Biochemical screening of high binding ligands and inhibition kinetic analysis and in vitro, in vivo antiviral efficacy of potential antiviral molecules: 19-24 5) Clinical testing of identified drugs in healthy patients for humans trials against SARS-CoV-2: 24-36 months
URL :
PI Details : Dr. Shailly Tomar , 01332-285803 , [email protected]

Project Title : Neutralizing Peptide Antibody Designed for Human Complement Fragment 5a (hC5a)

Expected Outcome :
Expected Timeline :
Remarks : COVID-19 is a disease caused by the SARS-CoV-2, which triggers aggressive inflammation response in the host body. Virus entry into the host cell triggers unregulated complement activation, resulting the onset of “cytokine storm”, which plays a significant role in acute lung injury. It is worth mentioning that respiratory distress is the prime reason behind the corona virus related mortality. Controlling the proinflammatory response of hC5a may work as an alternative to prevent acute lung injury triggered by the exposure to SARS coronavirus.
URL : https://www.iitbbs.ac.in/working-on-rational-design-and-development-of-neutralizing-peptide-antibody.php
PI Details : Dr. Soumendra Rana, [email protected]

Project Title : IIT Bhubaneswar working on Rational Design of Broad-Spectrum Antiviral Peptides Targeting SARS-CoV2-Spike Protein

Expected Outcome :
Expected Timeline :
Remarks : The structure of the SARS-CoV-2 spike protein bound to the human ACE2 receptor has recently been solved. Prima facie, the design of peptide-based inhibitor appears to be more suitable than the small molecule-based inhibitor.
URL : https://www.iitbbs.ac.in/working-on-rational-design-of-broad-spectrum-antiviral-peptides.php
PI Details : Dr. Soumendra Rana, [email protected]

Project Title : Engineering of epitope peptides from structural and non-structural proteins of coronavirus 2019-nCoV on Virus-Like particle (VLPs) to develop vaccine candidates.

Expected Outcome : Vaccine for SARS-Cov-2
Expected Timeline : 2 Years
Remarks : Depends on the receipt of grant
URL :
PI Details : Dr. Rajkumara, BT dept. , (040) 2301 7002 (O) , [email protected]

Project Title : Working on mRNA/peptide-based vaccine for SARS-Cov-2.

Expected Outcome : Ease of treatment
Expected Timeline : 18 Months
Remarks : NA
URL :
PI Details : Dr. Jyotsnendu Giri, BME dept. , (040) 2301 7115 (O) , [email protected]

Project Title : Identifying potential drug targets in the structural proteins of SARS-Cov-2.

Expected Outcome : Vaccine for SARS-Cov-2
Expected Timeline : 1.5 Years
Remarks : NA
URL :
PI Details : Dr. Thenmalarchelvi, BT dept. , (040) 2301 7067 (O) , [email protected]

Project Title : Virtual Screening and in vitro validation of SARS CoV-II Main Protease inhibitors

Expected Outcome : The project aims to deliver peptides, peptide analogs, or peptidomimetic sequences that could effectively inhibit the main protease associated with the SARS-CoV-II virus. These lead sequenced can be further modified in various ways e.g. grafted into a protease-resistant cyclic peptide, the addition of cell-penetrating peptides or insertion into PROTAC type multifunctional peptide to increase their potential for further development as therapeutics.
Expected Timeline : 1 year
Remarks : The work has been initiated, and submitted for funding.
URL :
PI Details : Sharad Gupta and Mithun Radhakrishna

Project Title : Small molecules screening on spike protein of Covid19

Expected Outcome : This project involves simulation studies and modelling of the spike protein of the virus which is the most important protein for the virus to invade into the host cells. Though a crystal structure of one of the spike protein is recently reported this protein has high chance of mutation rapidly. Our studies screen propose to study the in silico screening of the in house synthesized small molecules and their modelling studies using Schrodinger software and study the binding parts of this protein. This study would help in understanding the kind of small molecules that could eventually been tested as inhibitors of this spike protein. As a model study we started with NSP15 whose crystal structure is reported.
Expected Timeline : 6-8 months
Remarks : The work has been initiated
URL :
PI Details : Sivapriya Kirubakaran and Vijay Thriuvenkatam

Project Title : Scrutinizing the SARS-CoV-2 protein information for the designing an effective vaccine encompassing both the T-cell and B-cell epitopes

Expected Outcome : This present study provides an initial platform of the rapid generation of an efficacious protective vaccine for combating COVID-19
Expected Timeline : Project initiated
Remarks :
URL : https://www.biorxiv.org/content/10.1101/2020.03.26.009209v1?rss=1
PI Details : Dr. Amit Kumar, [email protected]

Project Title : International Network Research Project on "Stopping Covid-19 pandemic"

Expected Outcome : 1. Study Covid-19 virus interaction with human host cells 2. Study pathology of Covid-19 in human and identify susceptibility-resistance factors 3. Genotyping and whole genome sequencing of Covid-19 isolates from different countries 4. Cloud computing, machine learning (ML) and artificial intelligence (AI) as tools to identify primary drivers of COVID-19 infection.
Expected Timeline : Project initiated
Remarks :
URL :
PI Details : Prof. Dr. Avinash Sonawane, [email protected]

Project Title : Identifying Possible Potent Inhibitors against COVID-19 via Computational Drug Repurposing Study

Expected Outcome : Finding suitable drugs against COVID-19
Expected Timeline : Project initiated
Remarks :
URL :
PI Details : Dr. Parimal Kar , [email protected]

Project Title : Computer-Aided Drug Discovery against COVID-19

Expected Outcome : Finding new inhibitor
Expected Timeline : Project initiated
Remarks :
URL :
PI Details : Dr. Parimal Kar, [email protected]

Project Title : Identification of a Potential Peptide Inhibitor of SARS-CoV-2 Targeting its Entry into the Host Cells

Expected Outcome : The study would potentially result in the development of a novel peptide inhibitor as a therapeutic in SARS-CoV-2 infection.
Expected Timeline : Project initiated
Remarks :
URL : https://link.springer.com/article/10.1007/s40268-020-00312-5
PI Details : Dr. Mirza S. Baig, [email protected]

Project Title : Dual Targeting of 3CLpro and PLpro of SARS-CoV-2: A Novel Structure-Based Design Approach to treat COVID19 infection

Expected Outcome : The study will provide potential therapeutic candidates to treat COVID19 infection.
Expected Timeline : Project initiated
Remarks :
URL :
PI Details : Dr. Mirza S. Baig, [email protected]

Project Title : Structure-based design of novel peptidomimetics targeting the SARS-CoV-2 spike protein

Expected Outcome : The study is expected to explore novel peptide derivatives, which could inhibit the interaction of SARS-CoV-2 with ACE2 thereby blocking its Entry into the Host Cells.
Expected Timeline : Project initiated
Remarks :
URL :
PI Details : Dr. Mirza S. Baig, [email protected]

Project Title : Designing of a novel fusion peptide as a preventive as well as therapeutic, agent against SARS-CoV-2 infection

Expected Outcome : The study will provide a novel approach towards the prevention as well as treatment of COVID-19 infection utilizing a fusion peptide with immunogenic vaccine properties as well as therapeutic activities.
Expected Timeline : Project initiated
Remarks :
URL :
PI Details : Dr. Mirza S. Baig, [email protected]

Project Title : Indian spices and medicinal plants as antiviral against COVID-19 and other related viruses.

Expected Outcome : Identification of key ingredients from Indian spices and medicinal plants as antiviral (Proof of concept).
Expected Timeline : 9 Months
Remarks : Project may be extended further based on the proof of the concept data
URL :
PI Details : Prof. Vikash Kumar Dubey, [email protected]

Project Title : Standardized Extracts and Biomarkers of Andrographis peniculata(Kalmegh)

Expected Outcome : Immune Modulator Against CONVID-19
Expected Timeline : 1-2 years
Remarks : Proposal Submitted for funding
URL :
PI Details : Dr. Shreyans Kumar Jain, [email protected]

Project Title : Development of affordable synthetic route of Re-purposed small molecule drugs for the treatment of SARS-CoV-2

Expected Outcome : New Process Chemistry with Intellectual property (IP) value for the synthesis of drugs like Remdesivir, Galidesivir, Ritonavir, Lopinavir and Favipiravir
Expected Timeline : 12-18 months after obtaining funding
Remarks : Funding sought – Rs. 20 lakhs
URL :
Additional Info
PI Details : Dr. Parthasarathi Das, Dr. Somnath Yadav and Dr. Soumitra Maity , 9419227993 (PD), 9471191492 (SY) and 9471192521 (SM) , [email protected] [email protected] [email protected]